Key articles

Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008 Jun;134(7):1842-60. Abstract

Busuttil RA, Boussioutas A. Intestinal metaplasia: a premalignant lesion involved in gastric carcinogenesis. J Gastroenterol Hepatol. 2009 Feb;24(2):193-201. Abstract

Gupta S, Li D, El Serag HB, et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020 Feb;158(3):693-702.Full text  Abstract

Graham DY, Rugge M, Genta RM. Diagnosis: gastric intestinal metaplasia - what to do next? Curr Opin Gastroenterol. 2019 Nov;35(6):535-43.Full text  Abstract

Malfertheiner P, Megraud F, O'Morain CA, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30.Full text  Abstract

Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017 Feb;112(2):212-39.Full text  Abstract

Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019 Jul;157(1):44-53. Abstract

Howden CW. Emerging regimens for H. pylori infection should enhance efficacy and circumvent resistance. Dig Dis Sci. 2019 Oct;64(10):2691-2.Full text  Abstract

Busuttil RA, Boussioutas A. Intestinal metaplasia: a premalignant lesion involved in gastric carcinogenesis. J Gastroenterol Hepatol. 2009 Feb;24(2):193-201. Abstract

Reference articles

1. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008 Jun;134(7):1842-60. Abstract

2. Brand SJ, Stone D. Reciprocal regulation of antral gastrin and somatostatin gene expression by omeprazole-induced achlorhydria. J Clin Invest. 1988 Sep;82(3):1059-66.Full text  Abstract

3. Wu SV, Giraud A, Mogard M, et al. Effects of inhibition of gastric secretion on antral gastrin and somatostatin gene expression in rats. Am J Physiol. 1990 May;258(5 Pt 1):G788-93. Abstract

4. Manela FD, Ren J, Gao J, et al. Calcitonin gene-related peptide modulates acid-mediated regulation of somatostatin and gastrin release from rat antrum. Gastroenterology. 1995 Sep;109(3):701-6. Abstract

5. El-Zimaity H. Gastritis and gastric atrophy. Curr Opin Gastroenterol. 2008 Nov;24(6):682-6. Abstract

6. Sepulveda AR, Patil M. Practical approach to the pathologic diagnosis of gastritis. Arch Pathol Lab Med. 2008 Oct;132(10):1586-93. Abstract

7. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol. 2005 Mar;36(3):228-33. Abstract

8. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol. 1996 Oct;20(10):1161-81. Abstract

9. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008 Aug;40(8):650-8. Abstract

10. Rugge M, Fassan M, Pizzi M, et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol. 2011 Nov 7;17(41):4596-601.Full text  Abstract

11. Rugge M, Genta RM, Fassan M, et al. OLGA gastritis staging for the prediction of gastric cancer risk: a long-term follow-up study of 7436 patients. Am J Gastroenterol. 2018 Nov;113(11):1621-8. Abstract

12. Graham DY, Nurgalieva ZZ, El-Zimaity HM, et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol. 2006 Mar;4(3):306-14.Full text  Abstract

13. Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010 Jun;71(7):1150-8. Abstract

14. Betesh AL, Santa Ana CA, Cole JA, et al. Is achlorhydria a cause of iron deficiency anemia? Am J Clin Nutr. 2015 Jul;102(1):9-19.Full text  Abstract

15. Howard TA, Misra DN, Grove M, et al. Human gastric intrinsic factor expression is not restricted to parietal cells. J Anat. 1996 Oct;189 (Pt 2):303-13.Full text  Abstract

16. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019 Sep;157(3):682-91;e2.Full text  Abstract

17. Richards JB, Goltzman D. Proton-pump inhibitors: balancing the benefits and potential fracture risks. CMAJ. 2008 Aug 12;179(4):306-7.Full text  Abstract

18. Yang YX, Lewis JD, Epstein S, et al. Long-term proton-pump inhibitor therapy and risk of hip fracture. JAMA. 2006 Dec 27;296(24):2947-53. Abstract

19. Targownik LE, Lix LM, Metge CJ, et al. Use of proton-pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008 Aug 12;179(4):319-26.Full text  Abstract

20. Weck MN, Stegmaier C, Rothenbacher D, et al. Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany. Aliment Pharmacol Ther. 2007 Sep 15;26(6):879-87. Abstract

21. Bhutto A, Morley JE. The clinical significance of gastrointestinal changes with aging. Curr Opin Clin Nutr Metab Care. 2008 Sep;11(5):651-60. Abstract

22. Webb PM, Hengels KJ, Moller H, et al. The epidemiology of lower serum pepsinogen A levels and an international association with gastric cancer rates. EUROGAST Study Group. Gastroenterology. 1994 Nov;107(5):1335-44. Abstract

23. Busuttil RA, Boussioutas A. Intestinal metaplasia: a premalignant lesion involved in gastric carcinogenesis. J Gastroenterol Hepatol. 2009 Feb;24(2):193-201. Abstract

24. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med. 1996 May 27;156(10):1097-100. Abstract

25. Lombardo L, Leto R, Molinaro G, et al. Prevalence of atrophic gastritis in dyspeptic patients in Piedmont. A survey using the GastroPanel test. Clin Chem Lab Med. 2010 Sep;48(9):1327-32. Abstract

26. Kuipers EJ, Pérez-Pérez GI, Meuwissen SG, et al. Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst. 1995 Dec 6;87(23):1777-80. Abstract

27. Adamu MA, Weck MN, Gao L, et al. Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies. Eur J Epidemiol. 2010 Jul;25(7):439-48. Abstract

28. Song H, Held M, Sandin S, et al. Increase in the prevalence of atrophic gastritis among adults age 35 to 44 years old in northern Sweden between 1990 and 2009. Clin Gastroenterol Hepatol. 2015 Sep;13(9):1592-600;e1. Abstract

29. Zhang Y, Weck MN, Schöttker B, et al. Gastric parietal cell antibodies, Helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in Germany. Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):821-6.Full text  Abstract

30. Toh BH, Alderuccio F. Pernicious anemia. Autoimmunity. 2004 Jun;37(4):357-61. Abstract

31. Davidson RJ, Atrah HI, Sewell HF. Longitudinal study of circulating gastric antibodies in pernicious anaemia. J Clin Pathol. 1989 Oct;42(10):1092-5.Full text  Abstract

32. Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther. 2002 Jul;16(7):1249-59.Full text  Abstract

33. Venerito M, Varbanova M, Röhl FW, et al. Oxyntic gastric atrophy in Helicobacter pylori gastritis is distinct from autoimmune gastritis. J Clin Pathol. 2016 Aug;69(8):677-85. Abstract

34. Parsons BN, Ijaz UZ, D'Amore R, et al. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. PLoS Pathog. 2017 Nov;13(11):e1006653.Full text  Abstract

35. Argent RH, Thomas RJ, Aviles-Jimenez F, et al. Toxigenic Helicobacter pylori infection precedes gastric hypochlorhydria in cancer relatives, and H pylori virulence evolves in these families. Clin Cancer Res. 2008 Apr 1;14(7):2227-35. Abstract

36. Lewerin C, Jacobsson S, Lindstedt G, et al. Serum biomarkers for atrophic gastritis and antibodies against Helicobacter pylori in the elderly: implications for vitamin B12, folic acid, and iron status and response to oral vitamin therapy. Scand J Gastroenterol. 2008;43(9):1050-6. Abstract

37. D'Elios MM, Bergman MP, Azzurri A, et al. H+,K+-ATPase (proton-pump) is the target autoantigen of TH1-type cytotoxic T cells in autoimmune gastritis. Gastroenterology. 2001 Feb;120(2):377-86. Abstract

38. Claeys D, Faller G, Appelmelk BJ, et al. The gastric H+,K+-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology. 1998 Aug;115(2):340-7. Abstract

39. Miner P Jr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003 Dec;98(12):2616-20. Abstract

40. Shi S, Klotz U. Proton-pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008 Oct;64(10):935-51. Abstract

41. Fellenius E, Berglindh T, Sachs G. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+K+)ATPase. Nature. 1981 Mar 12;290(5802):159-61. Abstract

42. Trieu JA, Bilal M, Saraireh H, et al. Update on the diagnosis and management of gastric intestinal metaplasia in the USA. Dig Dis Sci. 2019 May;64(5):1079-88. Abstract

43. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015 Apr;148(4):719-31;e3.Full text  Abstract

44. Oh S, Kim N, Yoon H, et al. Risk factors of atrophic gastritis and intestinal metaplasia in first-degree relatives of gastric cancer patients compared with age-sex matched controls. J Cancer Prev. 2013 Jun;18(2):149-60.Full text  Abstract

45. Tan MC, Mallepally N, Liu Y, et al. Demographic and lifestyle risk factors for gastric intestinal metaplasia among US veterans. Am J Gastroenterol. 2020 Mar;115(3):381-7. Abstract

46. Pittayanon R, Rerknimitr R, Klaikaew N, et al. The risk of gastric cancer in patients with gastric intestinal metaplasia in 5-year follow-up. Aliment Pharmacol Ther. 2017 Jul;46(1):40-5. Abstract

47. Laszkowska M, Oh A, Hur C. Screening for upper gastrointestinal malignancies in the United States - which immigrant groups should be considered high-risk? Gastroenterology. 2020 Jan;158(1):4-8.Full text  Abstract

48. Graham DY, Alpert LC, Smith JL, et al. Iatrogenic Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol. 1988;83:192-9.

49. Saha A, Hammond CE, Trojanowska M, et al. Helicobacter pylori-induced H,K-ATPase alpha-subunit gene repression is mediated by NF-kappaB p50 homodimer promoter binding. Am J Physiol Gastrointest Liver Physiol. 2008 Mar;294(3):G795-807. Abstract

50. Kobayashi H, Kamiya S, Suzuki T, et al. The effect of Helicobacter pylori on gastric acid secretion by isolated parietal cells from a guinea pig: association with production of vacuolating toxin by H pylori. Scand J Gastroenterol. 1996 May;31(5):428-33. Abstract

51. Beales IL, Calam J. Inhibition of carbachol stimulated acid secretion by interleukin 1beta in rabbit parietal cells requires protein kinase C. Gut. 2001 Jun;48(6):782-9. Abstract

52. Liaskos C, Norman GL, Moulas A, et al. Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. Clin Chim Acta. 2010 Mar;411(5-6):411-5. Abstract

53. Kasperlik-Zaluska AA, Czarnocka B, Czech W, et al. Secondary adrenal insufficiency associated with autoimmune disorders: a report of twenty-five cases. Clin Endocrinol (Oxf). 1998 Dec;49(6):779-83. Abstract

54. De Block CE, De Leeuw IH, Van Gaal LF. Autoimmune gastritis in type 1 diabetes: a clinically oriented review. Clin Endocrinol Metab. 2008 Feb;93(2):363-71. Abstract

55. Chan JC, Liu HS, Kho BC, et al. Pattern of thyroid autoimmunity in Chinese patients with pernicious anemia. Am J Med Sci. 2009 Jun;337(6):432-7. Abstract

56. Checchi S, Montanaro A, Ciuoli C, et al. Prevalence of parietal cell antibodies in a large cohort of patients with autoimmune thyroiditis. Thyroid. 2010 Dec;20(12):1385-9. Abstract

57. Toh BH. Diagnosis and classification of autoimmune gastritis. Autoimmun Rev. 2014 Apr-May;13(4-5):459-62. Abstract

58. Venerito M, Radünz M, Reschke K, et al. Autoimmune gastritis in autoimmune thyroid disease. Aliment Pharmacol Ther. 2015 Apr;41(7):686-93. Abstract

59. Annibale B, Lahner E, Santucci A, et al. CagA and VacA are immunoblot markers of past Helicobacter pylori infection in atrophic body gastritis. Helicobacter. 2007 Feb;12(1):23-30. Abstract

60. Green LK, Graham DY. Gastritis in the elderly. Gastroenterol Clin North Am. 1990 Jun;19(2):273-92. Abstract

61. Karnes WE Jr, Samloff IM, Siurala M, et al. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology. 1991 Jul;101(1):167-74. Abstract

62. Cover TL, Blaser MJ. Helicobacter in health and disease. Gastroenterology. 2009 May;136(6):1863-73. Abstract

63. Woo JS, el-Zimaity HM, Genta RM, et al. The best gastric site for obtaining a positive rapid urease test. Helicobacter. 1996 Dec;1(4):256-9. Abstract

64. Vilaichone RK, Mahachai V, Graham DY. Helicobacter pylori diagnosis and treatment. Gastroenterol Clin North Am. 2006 Jun;35(2):229-47. Abstract

65. Kokkola A, Sjöblom SM, Haapiainen R, et al. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol. 1998 Jan;33(1):88-92. Abstract

66. Hou W, Schubert ML. Treatment of gastric carcinoids. Curr Treat Options Gastroenterol. 2007 Apr;10(2):123-33. Abstract

67. Eshmuratov A, Nah JC, Kim N, et al. The correlation of endoscopic and histological diagnosis of gastric atrophy. Dig Dis Sci. 2010 May;55(5):1364-75. Abstract

68. Hutchinson C, Geissler CA, Powell JJ, et al. Proton-pump inhibitors suppress absorption of dietary non-haem iron in hereditary hemochromatosis. Gut. 2007 Sep;56(9):1291-5. Abstract

69. Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J. 2004 Sep;97(9):887-9. Abstract

70. Annibale B, Capurso G, Chistolini A, et al. Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms. Am J Med. 2001 Oct 15;111(6):439-45. Abstract

71. Hershko C, Skikne B. Pathogenesis and management of iron deficiency anemia: emerging role of celiac disease, helicobacter pylori, and autoimmune gastritis. Semin Hematol. 2009 Oct;46(4):339-50. Abstract

72. Gupta S, Li D, El Serag HB, et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020 Feb;158(3):693-702.Full text  Abstract

73. Malfertheiner P. Helicobacter pylori infection - management from a European perspective. Dig Dis. 2014;32(3):275-80. Abstract

74. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994 Aug 1;121(3):161-7. Abstract

75. McCloy RF, Arnold R, Bardhan KD, et al. Pathophysiological effects of long-term acid suppression in man. Dig Dis Sci. 1995 Feb;40(2 Suppl):96S-120S. Abstract

76. Hung PD, Schubert ML, Mihas AA. Zollinger-Ellison syndrome. Curr Treat Options Gastroenterol. 2003 Apr;6(2):163-70. Abstract

77. Helgadóttir H, Lund SH, Gizurarson S, et al. Predictors of gastrin elevation following proton pump inhibitor therapy. J Clin Gastroenterol. 2020 Mar;54(3):227-34.Full text  Abstract

78. Scott JM. Folate and vitamin B12. Proc Nutri Soc. 1999 May;58(2):441-8. Abstract

79. Den Elzen WP, Groeneveld Y, De Ruijter W, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther. 2008 Mar 15;27(6):491-7. Abstract

80. Kowdley KV, Brown KE, Ahn J, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Aug;114(8):1202-18.Full text  Abstract

81. Lahner E, Annibale B. Pernicious anemia: new insights from a gastroenterological point of view. World J Gastroenterol. 2009 Nov 7;15(41):5121-8.Full text  Abstract

82. Richter C, Tanaka T, Yada RY. Mechanism of activation of the gastric aspartic proteinases: pepsinogen, progastricsin and prochymosin. Biochem J. 1998 Nov 1;335 (Pt 3):481-90.Full text  Abstract

83. Xu D, Fyfe JC. Cubilin expression and posttranslational modification in the canine gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol. 2000 Oct;279(4):G748-56. Abstract

84. Moestrup SK. New insights into carrier binding and epithelial uptake of the erythropoietic nutrients cobalamin and folate. Curr Opin Hematol. 2006 May;13(3):119-23. Abstract

85. Oh DS, Wang HS, Ohning GV, et al. Validation of a new endoscopic technique to assess acid output in Zollinger-Ellison Syndrome. Clin Gastroenterol Hepatol. 2006 Dec;4(12):1467-73. Abstract

86. Moore EW, Scarlata RW. The determination of gastric acidity by the glass electrode. Gastroenterology. 1965 Aug;49:178-88. Abstract

87. Al-Omari FA, Matalka II, Al-Jarrah MA, et al. An intelligent decision support system for quantitative assessment of gastric atrophy. J Clin Pathol. 2011 Apr;64(4):330-7. Abstract

88. Bettington M, Brown I. Autoimmune gastritis: novel clues to histological diagnosis. Pathology. 2013 Feb;45(2):145-9. Abstract

89. Graham DY, Rugge M, Genta RM. Diagnosis: gastric intestinal metaplasia - what to do next? Curr Opin Gastroenterol. 2019 Nov;35(6):535-43.Full text  Abstract

90. Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007 Aug;102(8):1808-25.Full text  Abstract

91. Malfertheiner P, Megraud F, O'Morain CA, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30.Full text  Abstract

92. Hwang YJ, Kim N, Lee HS, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years. Aliment Pharmacol Ther. 2018 Feb;47(3):380-90. Abstract

93. Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018 Mar 22;378(12):1085-95.Full text  Abstract

94. Malfertheiner P. Gastric atrophy reversible or irreversible after Helicobacter pylori eradication - an open question. Digestion. 2011;83(4):250-2.Full text  Abstract

95. Elitsur Y, Tolia V, Gilger MA, et al. Urea breath test in children: the United States prospective, multicenter study. Helicobacter. 2009 Apr;14(2):134-40. Abstract

96. Shimoyama T, Oyama T, Matsuzaka M, et al. Comparison of a stool antigen test and serology for the diagnosis of Helicobacter pylori infection in mass survey. Helicobacter. 2009 Apr;14(2):87-90. Abstract

97. Granstrom M, Lehours P, Bengtsson C, et al. Diagnosis of Helicobacter pylori. Helicobacter. 2008 Oct;13(suppl 1):7-12. Abstract

98. Stenstrom B, Mendis A, Marshall B. Helicobacter pylori - the latest in diagnosis and treatment. Aus Fam Physician. 2008 Aug;37(8):608-12. Abstract

99. Calvet X, Ramírez Lázaro MJ, Lehours P, et al. Diagnosis and epidemiology of Helicobacter pylori infection. Helicobacter. 2013 Sep;18(suppl 1):5-11.Full text  Abstract

100. Kumar V. Pernicious anemia. MLO Med Lab Obs. 2007 Feb;39(2):28, 30-1. Abstract

101. Scalabrino G. Cobalamin (vitamin B12) in subacute combined degeneration and beyond: traditional interpretations and novel theories. Exp Neurol. 2005 Apr;192(2):463-79. Abstract

102. Holt PR. Intestinal malabsorption in the elderly. Dig Dis. 2007;25(2):144-50. Abstract

103. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007 Sep;102(9):2047-56;quiz 2057. Abstract

104. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005 Dec 21;294(23):2989-95. Abstract

105. Goel GA, Deshpande A, Lopez R, et al. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol. 2012 Apr;10(4):422-7.Full text  Abstract

106. Zucker DK, Livingston RL, Nakra R, et al. B12 deficiency and psychiatric disorders: case report and literature review. Biol Psychiatry. 1981 Feb;16(2):197-205. Abstract

107. Graells J, Ojeda RM, Muniesa C, et al. Glossitis with linear lesions: an early sign of vitamin B12 deficiency. J Am Acad Dermatol. 2009 Mar;60(3):498-500. Abstract

108. Kumar G, Vaidyanathan L, Stead LG. Images in emergency medicine: koilonychia, or spoon-shaped nails, is generally associated with iron-deficiency anemia. Ann Emerg Med. 2007 Feb;49(2):243,250. Abstract

109. Ozturk E, Yesilova Z, Ilgan S, et al. Performance of acidified (14)C-urea capsule breath test during pantoprazole and ranitidine treatment. J Gastroenterol Hepatol. 2009;24:1248-1251. Abstract

110. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis. 2007 Feb;8(1):8-14. Abstract

111. Sipponen P, Ranta P, Helske T, et al. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol. 2002 Jul;37(7):785-91. Abstract

112. Vaananen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test: correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol. 2003 Aug;15(8):885-91. Abstract

113. Leja M, Kupcinskas L, Funka K, et al. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci. 2009 Nov;54(11):2377-84. Abstract

114. Antico A, Tampoia M, Villalta D, et al. Clinical usefulness of the serological gastric biopsy for the diagnosis of chronic autoimmune gastritis. Clin Dev Immunol. 2012;2012:520970.Full text  Abstract

115. Agreus L, Kuipers EJ, Kupcinskas L, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol. 2012 Feb;47(2):136-47.Full text  Abstract

116. Loong TH, Soon NC, Nik Mahmud NRK, et al. Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus. Biomed Rep. 2017 Nov;7(5):460-8.Full text  Abstract

117. Tong Y, Wu Y, Song Z, et al. The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China: a diagnostic clinical research. BMC Gastroenterol. 2017 Jul 20;17(1):88.Full text  Abstract

118. Bornschein J, Selgrad M, Wex T, et al. Serological assessment of gastric mucosal atrophy in gastric cancer. BMC Gastroenterol. 2012 Jan 31;12:10.Full text  Abstract

119. Kikuchi S, Kato M, Katsuyama T, et al. Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection. Helicobacter. 2006 Jun;11(3):147-51. Abstract

120. McNicholl AG, Forné M, Barrio J, et al. Accuracy of GastroPanel for the diagnosis of atrophic gastritis. Eur J Gastroenterol Hepatol. 2014;26:941-948.Full text  Abstract

121. Lundell L, Vieth M, Gibson F, et al. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015 Sep;42(6):649-63.Full text  Abstract

122. ASGE Standards of Practice Committee, Evans JA, Chandrasekhara V, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest Endosc. 2015;82:1-8. Abstract

123. Storm AC, Fishman DS, Buxbaum JL, et al. American Society for Gastrointestinal Endoscopy guideline on informed consent for GI endoscopic procedures. Gastrointest Endosc. 2022 Feb;95(2):207-15.Full text  Abstract

124. Toyokawa T, Suwaki K, Miyake Y, et al. Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study. J Gastroenterol Hepatol. 2010 Mar;25(3):544-7. Abstract

125. De Vries AC, Kuipers EJ, Rauws EA. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol. 2009 Jun;104(6):1342-5. Abstract

126. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014 Feb;12(2):177-86;e3;discussion e12-3.Full text  Abstract

127. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017 Feb;112(2):212-39.Full text  Abstract

128. McNicholl AG, Bordin DS, Lucendo A, et al. Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients. Clin Gastroenterol Hepatol. 2020 Jan;18(1):89-98. Abstract

129. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016 Jul;151(1):51-69;e14. Abstract

130. Wang Z, Wu S. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Singapore Med J. 2012 Apr;53(4):273-6.Full text  Abstract

131. Akyildiz M, Akay S, Musoglu A, et al. The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication. Eur J Intern Med. 2009 Jan;20(1):53-7. Abstract

132. Niv Y. Doxycycline in eradication therapy of Helicobacter pylori - a systematic review and meta-analysis. Digestion. 2016;93(2):167-73.Full text  Abstract

133. Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017 Aug;22(4). Abstract

134. Alsamman MA, Vecchio EC, Shawwa K, et al. Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA. Dig Dis Sci. 2019 Oct;64(10):2893-8. Abstract

135. Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010 Jun;15(3):233-8. Abstract

136. Calvet X, García N, López T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000 May;14(5):603-9.Full text  Abstract

137. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol. 2003 Jun;17 suppl B:36B-40B. Abstract

138. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007 Oct 16;147(8):553-62. Abstract

139. Flores HB, Salvana A, Ang ELR, et al. Duration of proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Gastroenterology. 2010;138(S-340).

140. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013 Dec 11;(12):CD008337. Abstract

141. Liou JM, Chen CC, Lee YC, et al. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016 Feb;43(4):470-81.Full text  Abstract

142. Fiorini G, Zullo A, Vakil N, et al. Rifabutin triple therapy is effective in patients with multidrug-resistant strains of Helicobacter pylori. J Clin Gastroenterol. 2018 Feb;52(2):137-40. Abstract

143. Graham DY, Canaan Y, Maher J, et al. Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial. Ann Intern Med. 2020 Jun 16;172(12):795-802. Abstract

144. Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019 Jul;157(1):44-53. Abstract

145. Howden CW. Emerging regimens for H. pylori infection should enhance efficacy and circumvent resistance. Dig Dis Sci. 2019 Oct;64(10):2691-2.Full text  Abstract

146. Yang X, Wang JX, Han SX, et al. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: a systematic review and meta-analysis. Medicine (Baltimore). 2019 Feb;98(7):e14396.Full text  Abstract

147. Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013 Jul;11(7):802-7;e1.Full text  Abstract

148. Vakil N. H. pylori treatment: new wine in old bottles? Am J Gastroenterol. 2009 Jan;104(1):26-30. Abstract

149. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007 Sep;133(3):985-1001. Abstract

150. Graham DY, Rimbara E. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol. 2011 Apr;45(4):309-13. Abstract

151. Hsu PI, Wu DC, Wu JY, et al. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011 Apr;16(2):139-45. Abstract

152. Hu Y, Zhu Y, Lu N-H. Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance front cell. Infect Microbiol. 2017 May 5;7:168.Full text  Abstract

153. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012 Jan;35(2):209-21.Full text  Abstract

154. Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018 Nov;155(5):1372-82;e17.Full text  Abstract

155. Shiota S, Reddy R, Alsarraj A, et al. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol. 2015 Sep;13(9):1616-24.Full text  Abstract

156. Wang YK, Kuo FC, Liu CJ, et al. Diagnosis of Helicobacter pylori infection: current options and developments. World J Gastroenterol. 2015 Oct 28;21(40):11221-35.Full text  Abstract

157. El-Serag HB, Kao JY, Kanwal F, et al. Houston Consensus Conference on testing for Helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol. 2018 Jul;16(7):992-1002;e6.Full text  Abstract

158. Laine L, Estrada R, Trujillo M, et al. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med. 1998 Oct 1;129(7):547-50. Abstract

159. Kodama M, Murakami K, Okimoto T, et al. Influence of proton pump inhibitor treatment on Helicobacter pylori stool antigen test. World J Gastroenterol. 2012 Jan 7;18(1):44-8.Full text  Abstract

160. Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017 Nov;4(11):e524-33. Abstract

161. Lahner E, Annibale B, Delle Fave G. Systemic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther. 2009 Feb 15;29(4):379-86. Abstract

162. Lahner E, Annibale B, Delle Fave G. Systemic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther. 2009 Jun 15;29(12):1219-29. Abstract

163. Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmac. 1991 Nov;32(5):569-72. Abstract

164. Soons PA, van den Berg G, Danhof M, et al. Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol. 1992;42(3):319-24. Abstract

165. Checchi S, Montanaro A, Pasqui L, et al. L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J Clin Endocrinol Metab. 2008 Feb;93(2):465-9. Abstract

166. Fishbane S, Ungureanu VD, Maeska JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996 Oct;28(4):529-34. Abstract

167. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999 Mar;33(3):464-70. Abstract

168. Cauley JA, Lacroix AZ, Wu L, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med. 2008 Aug 19;149(4):242-50. Abstract

169. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997 Sep 4;337(10):670-6. Abstract

170. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007 Aug 25;370(9588):657-66. Abstract

171. Hunt RH, Scarpignato C. Potent acid suppression with PPIs and P-CABs: what's new? Curr Treat Options Gastroenterol. 2018 Dec;16(4):570-90. Abstract

172. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017 Jul;46(2):106-14. Abstract

173. Li M, Oshima T, Horikawa T, et al. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018 Aug;23(4):e12495. Abstract

174. Tanabe H, Yoshino K, Ando K, et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob. 2018 Jun 28;17(1):29.Full text  Abstract

175. Banks M, Graham D, Jansen M, et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019 Sep;68(9):1545-75.Full text  Abstract

176. Busuttil RA, Boussioutas A. Intestinal metaplasia: a premalignant lesion involved in gastric carcinogenesis. J Gastroenterol Hepatol. 2009 Feb;24(2):193-201. Abstract

177. Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006 Apr;63(4):570-80. Abstract

178. Lochhead P, El-Omar EM. Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol. 2007;21(2):281-97. Abstract

179. Sjöblom SM, Sipponen P, Järvinen H. Gastroscopic follow up of pernicious anaemia patients. Gut. 1993 Jan;34(1):28-32. Abstract

180. Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med. 1997 Nov 13;337(20):1441-8. Abstract

181. Heidelbaugh JJ, Kim AH, Chang R, et al. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012 Jul;5(4):219-32.Full text  Abstract

Use of this content is subject to our disclaimer